Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00445679
Status:
COMPLETED
Last Update Posted:
2013-11-03
First Post:
2007-03-06
Brief Title:
Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-blind Paroxetine-referenced Parallel-group Study to Evaluate the Safety Efficacy and Tolerability of 3 Fixed Doses 50mg 100mg AND 200mg of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the safety tolerability and efficacy of desvenlafaxine succinate sustained release DVS SR in subjects with major depressive disorder
Detailed Description:
The primary objective of this study is to investigate the efficacy safety and tolerability of desvenlafaxine succinate sustained release DVS SR in Chinese Taiwanese South Korean and Indian subjects with major depressive disorder MDD receiving daily doses of 50 mg 100 mg or 200 mg The secondary objective is to obtain additional information regarding the efficacy of DVS SR in subjects with MDD receiving daily doses of 50 mg 100 mg or 200 mg Additional objectives include obtaining general and functional quality of life outcome data
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None